You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 782-D Systemic delivery of novel, allosteric STING agonist CRD3874-SI leads to robust anti-cancer activity by generating pro-inflammatory Type I IFN signals while blocking proton channel mediated toxicity

Article Text

Article menu

Download PDFPDF

Regular Abstracts – Part 2
Clinical Trial In Progress
782-D Systemic delivery of novel, allosteric STING agonist CRD3874-SI leads to robust anti-cancer activity by generating pro-inflammatory Type I IFN signals while blocking proton channel mediated toxicity

https://doi.org/10.1136/jitc-2023-SITC2023.0782-D

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.